Compare GSK plc (GSK) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Centrus Energy Corp — how do they compare? GSK plc trades at $52.58 (market cap $101.34B), while Centrus Energy Corp trades at $146.88 (market cap $3.08B). The key difference: GSK plc is far larger — about 32.9× Centrus Energy Corp's market cap, and GSK plc pays a 3.49% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals.
| GSK | LEU | |
|---|---|---|
Market Cap | $101.34B | $3.08B |
Sector | Health | Energy |
52-Week High | $61.18 | $436.00 |
52-Week Low | $36.20 | $146.61 |
Enterprise Value | $121.95B | $2.39B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Centrus Energy (LEU) trades at $147.83, down 7.25% today, with a bearish technical signal from moving averages. The stock shows mixed fundamentals with a high P/E of 56.92 but strong recent contract wins, including a $1 billion DOE award for nuclear fuel production. Recent earnings beat expectations in Q1 2026 but missed in prior quarters. Positive news includes inclusion in the S&P SmallCap 600 and a letter of intent with Oklo for HALEU supply.
Outlook is cautiously optimistic due to strategic government contracts and nuclear industry tailwinds, but high valuation and recent earnings misses pose risks. Analyst consensus is a Buy with a $223.14 price target, implying significant upside. Key risks include execution on new contracts and volatility in uranium markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
